Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
767 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016, provides an overview of the Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape. Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. It then invades the blood. Symptoms usually develop slowly. Symptoms of CLL include abnormal bruising (if platelets are low), fever, infections that keep coming back (recur), loss of appetite or becoming full too quickly (early satiety) and weight loss. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 5, 43, 45, 1, 3, 54, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 6, 8 and 7 molecules, respectively.Chronic Lymphocytic Leukemia (CLL). Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL) (Oncology). - The pipeline guide reviews pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 7 Chronic Lymphocytic Leukemia (CLL) Overview 8 Therapeutics Development 9 Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies 11 Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes 20 Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance 22 Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies 26 Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes 40 Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 42 Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 141 Drug Profiles 168 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 713 Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 726 Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 728 Appendix 745
List of Tables
Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H2 2016 30 Number of Products under Development for Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H2 2016 31 Number of Products under Development by Companies, H2 2016 33 Number of Products under Development by Companies, H2 2016 (Contd..1) 34 Number of Products under Development by Companies, H2 2016 (Contd..2) 35 Number of Products under Development by Companies, H2 2016 (Contd..3) 36 Number of Products under Development by Companies, H2 2016 (Contd..4) 37 Number of Products under Development by Companies, H2 2016 (Contd..5) 38 Number of Products under Development by Companies, H2 2016 (Contd..6) 39 Number of Products under Development by Companies, H2 2016 (Contd..7) 40 Number of Products under Investigation by Universities/Institutes, H2 2016 42 Comparative Analysis by Late Stage Development, H2 2016 43 Comparative Analysis by Clinical Stage Development, H2 2016 44 Comparative Analysis by Early Stage Development, H2 2016 45 Comparative Analysis by Unknown Stage Development, H2 2016 46 Products under Development by Companies, H2 2016 47 Products under Development by Companies, H2 2016 (Contd..1) 48 Products under Development by Companies, H2 2016 (Contd..2) 49 Products under Development by Companies, H2 2016 (Contd..3) 50 Products under Development by Companies, H2 2016 (Contd..4) 51 Products under Development by Companies, H2 2016 (Contd..5) 52 Products under Development by Companies, H2 2016 (Contd..6) 53 Products under Development by Companies, H2 2016 (Contd..7) 54 Products under Development by Companies, H2 2016 (Contd..8) 55 Products under Development by Companies, H2 2016 (Contd..9) 56 Products under Development by Companies, H2 2016 (Contd..10) 57 Products under Development by Companies, H2 2016 (Contd..11) 58 Products under Development by Companies, H2 2016 (Contd..12) 59 Products under Development by Companies, H2 2016 (Contd..13) 60 Products under Investigation by Universities/Institutes, H2 2016 61 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 62 Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H2 2016 63 Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc, H2 2016 64 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 65 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aeglea BioTherapeutics Inc, H2 2016 66 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Altor BioScience Corp, H2 2016 67 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Amgen Inc, H2 2016 68 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aprea AB, H2 2016 69 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aptevo Therapeutics Inc, H2 2016 70 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Arno Therapeutics Inc, H2 2016 71 Chronic Lymphocytic Leukemia (CLL) - Pipeline by ArQule Inc, H2 2016 72 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc, H2 2016 73 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals Inc, H2 2016 74 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Baliopharm AG, H2 2016 75 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bayer AG, H2 2016 76 Chronic Lymphocytic Leukemia (CLL) - Pipeline by BeiGene Ltd, H2 2016 77 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 78 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Biogen Inc, H2 2016 79 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bionomics Ltd, H2 2016 80 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bionovis SA, H2 2016 81 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Biothera Pharmaceutical Inc, H2 2016 82 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H2 2016 83 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Company, H2 2016 84 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corp, H2 2016 85 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellectis SA, H2 2016 86 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellular Biomedicine Group Inc, H2 2016 87 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Coherus BioSciences Inc, H2 2016 88 Chronic Lymphocytic Leukemia (CLL) - Pipeline by CrystalGenomics Inc, H2 2016 89 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 90 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 91 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Eli Lilly and Company, H2 2016 92 Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 93 Chronic Lymphocytic Leukemia (CLL) - Pipeline by GeneaMed Ltd, H2 2016 94 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Genentech Inc, H2 2016 95 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Genor BioPharma Co Ltd, H2 2016 96 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Gilead Sciences Inc, H2 2016 97 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Grupo Ferrer Internacional SA, H2 2016 98 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hutchison MediPharma Ltd, H2 2016 99 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hybrigenics SA, H2 2016 100 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Igenica Biotherapeutics Inc, H2 2016 101 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immatics Biotechnologies GmbH, H2 2016 102 Chronic Lymphocytic Leukemia (CLL) - Pipeline by ImmunoGen Inc, H2 2016 103 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics Inc, H2 2016 104 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Incyte Corp, H2 2016 105 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Inflection Biosciences Ltd, H2 2016 106 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innate Pharma SA, H2 2016 107 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innovent Biologics Inc, H2 2016 108 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Johnson & Johnson, H2 2016 109 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Juno Therapeutics Inc, H2 2016 110 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kancera AB, H2 2016 111 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics Inc, H2 2016 112 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kite Pharma Inc, H2 2016 113 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Les Laboratoires Servier SAS, H2 2016 114 Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB SA, H2 2016 115 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lymphocyte Activation Technologies SA, H2 2016 116 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Medicenna Therapeutics Inc, H2 2016 117 Chronic Lymphocytic Leukemia (CLL) - Pipeline by MENTRIK Biotech LLC, H2 2016 118 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Merck & Co Inc, H2 2016 119 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Merck KGaA, H2 2016 120 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Mesoblast Ltd, H2 2016 121 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 122 Chronic Lymphocytic Leukemia (CLL) - Pipeline by MorphoSys AG, H2 2016 123 Chronic Lymphocytic Leukemia (CLL) - Pipeline by NantKwest Inc, H2 2016 124 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Nordic Nanovector ASA, H2 2016 125 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Novartis AG, H2 2016 126 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Oncternal Therapeutics, Inc., H2 2016 127 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 128 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Panacea Biotec Ltd, H2 2016 129 Chronic Lymphocytic Leukemia (CLL) - Pipeline by PEP-Therapy SAS, H2 2016 130 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Pfizer Inc, H2 2016 131 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Pharmacyclics Inc, H2 2016 132 Chronic Lymphocytic Leukemia (CLL) - Pipeline by PIQUR Therapeutics AG, H2 2016 133 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Portola Pharmaceuticals Inc, H2 2016 134 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Redx Pharma Plc, H2 2016 135 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Respiratorius AB, H2 2016 136 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Revitope Oncology, Inc., H2 2016 137 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Rhizen Pharmaceuticals SA, H2 2016 138 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sandoz International GmbH, H2 2016 139 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sanofi, H2 2016 140 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Selvita SA, H2 2016 141 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Simcere Pharmaceutical Group, H2 2016 142 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sorrento Therapeutics Inc, H2 2016 143 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Supratek Pharma Inc, H2 2016 144 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 145 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Targazyme Inc, H2 2016 146 Chronic Lymphocytic Leukemia (CLL) - Pipeline by TG Therapeutics Inc, H2 2016 147 Chronic Lymphocytic Leukemia (CLL) - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016 148 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Theravectys SA, H2 2016 149 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tolero Pharmaceuticals Inc, H2 2016 150 Chronic Lymphocytic Leukemia (CLL) - Pipeline by TRACON Pharmaceuticals Inc, H2 2016 151 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tragara Pharmaceuticals Inc, H2 2016 152 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Trillium Therapeutics Inc, H2 2016 153 Chronic Lymphocytic Leukemia (CLL) - Pipeline by United BioPharma, Inc., H2 2016 154 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Unum Therapeutics Inc, H2 2016 155 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Verastem Inc, H2 2016 156 Chronic Lymphocytic Leukemia (CLL) - Pipeline by VioQuest Pharmaceuticals Inc, H2 2016 157 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Viralytics Ltd, H2 2016 158 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Xencor Inc, H2 2016 159 Chronic Lymphocytic Leukemia (CLL) - Pipeline by ZIOPHARM Oncology Inc, H2 2016 160 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Zymeworks Inc, H2 2016 161 Assessment by Monotherapy Products, H2 2016 162 Assessment by Combination Products, H2 2016 163 Number of Products by Stage and Target, H2 2016 165 Number of Products by Stage and Mechanism of Action, H2 2016 175 Number of Products by Stage and Route of Administration, H2 2016 186 Number of Products by Stage and Molecule Type, H2 2016 188 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H2 2016 734 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..1), H2 2016 735 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..2), H2 2016 736 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..3), H2 2016 737 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..4), H2 2016 738 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..5), H2 2016 739 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..6), H2 2016 740 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..7), H2 2016 741 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..8), H2 2016 742 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..9), H2 2016 743 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..10), H2 2016 744 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..11), H2 2016 745 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..12), H2 2016 746 Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H2 2016 747 Chronic Lymphocytic Leukemia (CLL) - Discontinued Products (Contd..1), H2 2016 748
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
